Trinity Biotech (TRIB) Notes Payables (2010 - 2025)

Trinity Biotech (TRIB) has reported Notes Payables for 6 consecutive years, with $1.1 million the latest figure, recorded in Q2 2025.

• Quarterly Notes Payables fell 22.85% year-over-year to $1.1 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $1.1 million (down 22.85% YoY) and the FY2024 annual result came in at $1.7 million, up 215.21% from the prior year.
• Notes Payables declined to $1.1 million in Q2 2025 per TRIB's latest filing, from $1.7 million in the prior quarter.
• Over the last five years, Notes Payables for TRIB reached as high as $83.3 million in Q4 2021 and fell as low as $526000.0 in Q4 2023.
• A 5-year average of $7.2 million and a median of $1.5 million in 2023 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2022 — Notes Payables plunged 98.12% — and 2024, when it surged 215.21%.
• Year by year, Notes Payables stood at $83.3 million in 2021, then tumbled by 98.12% to $1.6 million in 2022, then sank by 66.48% to $526000.0 in 2023, then jumped by 215.21% to $1.7 million in 2024, then sank by 32.81% to $1.1 million in 2025.
• According to Business Quant data, Notes Payables over the past three periods registered $1.1 million, $1.7 million, and $596000.0 for Q2 2025, Q4 2024, and Q3 2024 respectively.